A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Trial Profile

A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 03 May 2018

At a glance

  • Drugs BMS 986205 (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 26 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to change in business objectives
    • 15 Mar 2018 Planned End Date changed from 23 May 2025 to 20 Aug 2025.
    • 15 Mar 2018 Planned primary completion date changed from 26 Jan 2021 to 25 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top